These forms are reproduced from a morphoic agonist maintenance treatment: A pharmacy head for methadone and buprenorphine for opioid use Source: Isaac, P., Janecek, E, Kalvik, A. -Zhang, M. (2015). Opioid Agonist Maintenance Treatment: A chief pharmacist for methadone and buprenorphine for opioid use disorder. Toronto: Centre for Addiction and Mental Health. The pharmacist-patient treatment agreement deals with the delivery hours and the observed dosing method. It also helps pharmacists discuss concerns and implications around alcohol and other sedative drugs with patients at the beginning of their treatment program and minimize the likelihood of introducing patients who are poisoned by the pharmacy. When first distributing doses taken at home, the pharmacist should discuss the safe use and storage of the drug with the patient and document this discussion. Pharmacists are encouraged to have patients sign a written agreement, such as the samples provided here, to ensure that prevention and expectations are clearly understood.